Enhancement of Fibrinolysis by EF6265 [(S)-7-Amino-2-[[[(R)-2-methyl-1-(3-phenylpropanoylamino)propyl] hydroxyphosphinoyl] methyl]heptanoic Acid], a Specific Inhibitor of Plasma Carboxypeptidase B

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 607-615

  Suzuki, Kokichi ^a   Muto, Yuko ^a   Fushihara, Kenichi ^a   Kanemoto, Ken Ichi ^a   Iida, Hiroyuki ^a   Sato, Eriko ^a   Kikuchi, Chika ^a   Matsushima, Tetsuya ^a   Kato, Emiko ^a   Nomoto, Masahiro ^a   Yoshioka, Shin ^a   Ishii, Hidemi ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[7 AMINO 2 [[[2 METHYL 1 (3 PHENYLPROPANOYLAMINO)PROPYL]HYDROXYPHOSPHINOYL]METHYL]HEPTANOIC ACID]; ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; CARBOXYPEPTIDASE B; D DIMER; EF 6265; ENZYME PRECURSOR; FIBRIN; HEPTANOIC ACID DERIVATIVE; LIGAND; LYSINE; PHOSPHINIC ACID DERIVATIVE; PLASMINOGEN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CARBOXY TERMINAL SEQUENCE; CONCENTRATION RESPONSE; DOWN REGULATION; DRUG INHIBITION; DRUG SPECIFICITY; ENZYME BLOOD LEVEL; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; IC 50; MALE; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOEMBOLISM; THROMBOSIS;

AMINO ACIDS; ANIMALS; ARTERIOVENOUS SHUNT, SURGICAL; BLEEDING TIME; CARBOXYPEPTIDASE U; ENZYME INHIBITORS; FIBRINOLYSIS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PHOSPHINIC ACIDS; RATS; RATS, WISTAR; THROMBOPLASTIN; THROMBOSIS;

EID: 11144356646     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062729     Document Type: Article

References (39)

1. Aoshima K, Asakura H, Yamazaki M, Saito M, Kumabashiri I, Morishita E, Ontachi Y, Mizutani T, Ichino T, and Matsuda T (1998) Treatment of disseminated intravascular coagulation (DIC) with all-trans retinoic acid in an endotoxin-induced rat model. Semin Thromb Hemost 24:227-231.
2. Bajzar L (2000) Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 20:2511-2518.
3. Bajzar L, Manuel R, and Nesheim ME (1995) Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 270:14477-14484.
4. Baylis EK, Campbell CD, and Dingwall JG (1984) 1-Amioalkylphosphonous acids. Part 1. Isosteres of the protein amino acids. J Chem Soc Parkin Trans 1:2845-2853.
5. Bloom JC, Sellers TS, Gries GC, Wheeldon EB, O'Brien SR, and Lewis HB (1988) The effects of human recombinant tissue-type plasminogen activator on clinical and laboratory parameters of hemostasis and systemic plasminogen activation in the dog and the rat. Thromb Haemost 60:271-279.
6. Bouma BN and Meijers JC (2003) Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 1:1566-1574.
7. Cushman DW and Cheung HS (1971) Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20:1637-1648.
8. Esmon CT (1989) The role of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem 264:4743-4746.
9. Fleury V and Angles-Cano E (1991) Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 30:7630-7638.
10. Hara T, Yokoyama A, Tanabe K, Ishihara H, and Iwamoto M (1995) DX-9065a, an orally active, specific inhibitor of factor Xa, inhibits thrombosis without affecting bleeding time in rats. Thromb Haemost 74:635-639.
11. Hasegawa N, Kandra TG, Husari AW, Veiss S, Hart WT, Hedgpeth J, Wydro R, and Raffin TA (1996) The effects of recombinant human thrombomodulin on endotoxin-induced multiple-system organ failure in rats. Am J Respir Crit Care Med 153:1831-1837.
12. Hosaka Y, Takahashi Y, and Ishii H (1998) Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 79:371-377.
13. Ishii H (1994) The detection and measurement of thrombomodulin, in Thrombin, Thrombomodulin and the Control of Haemostasis (Giddings JC ed) pp 121-141, RG Landes, Austin, TX.
14. Kato H, Adachi N, Ohno Y, Iwanaga S, Takada K, and Sakakibara S (1980) New fluorogenic peptide substrates for plasmin. J Biochem 88:183-190.
15. Kawabata S, Miura T, Morita T, Kato H, Fujikawa K, Iwanaga S, Takada K, Kimura T, and Sakakibara S (1988) Highly sensitive peptide-4-methylcoumaryl-7-amide substrates for blood-clotting proteases and trypsin. Eur J Biochem 172:17-25.
16. Kawabata S, Morita T, Iwanaga S, and Igarashi H (1985) Difference in enzymatic properties between alpha-thrombin-staphylocoagulase complex and free alpha-thrombin. J Biochem. 97:1073-1078.
17. Klement PK, Liao P, and Bajzar L (1999) A novel approach to arterial thrombolysis. Blood 94:2735-2743.
18. Matsuda T, Ogawara M, Miura R, Seki T, Matsumoto T, Teramura Y, and Nakamura K (1984) Selective determination of alpha 2-plasmin inhibitor activity in plasma using chromogenic substrate. Thromb Res 33:379-388.
19. Miller DJ, Hammond SM, Anderluzzi D, and Bugg TDH (1998) Aminoalkylphosphinate inhibitors of D-Ala-D-Ala adding enzyme. J Chem Soc Parkin Trans 1:131-142.
20. Minnema MC, Friederich PW, Levi M, von dem Borne PAK, Mosnier LO, Meijers JCM, Biemond BJ, Hack CE, Bouma BN, and ten Cate H (1998) Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI: in vivo evidence for a role of factor XI as an anti-fibrinolytic factor. J Clin Investig 101:10-14.
21. Montaner J, Ribo M, Monasterio J, Molina CA, and Alvarez-Sabin J (2003) Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 34:1038-1040.
22. Morita T, Kato H, Iwanaga S, Takada K, and Kimura T (1977) New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins and urokinase. J Biochem 82:1495-1498.
23. Mosnier LO, von dem Borne PA, Meijers JC, and Bouma BN (1998) Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 80:829-835.
24. Muto Y, Suzuki K, Sato E, and Ishii H (2003) Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 461:181-189.
25. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, and Verhallen P (2000) An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 98:333-342.
26. Nagashima M, Yin ZF, Zhao L, White K, Zhu Y, Lasky N, Halks-Miller M, Broze GJ Jr, Fay WP, and Morser J (2002) Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Investig 109:101-110.
27. Redlitz A, Tan TK, Eaton DL, and Plow EF (1995) Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Investig 96:2534-2538.
28. Rijken DC and Sakharov DV (2001) Basic principles in thrombolysis: regulatory role of plasminogen. Thromb Res 103:S41-S49.
29. Sakharov DV, Plow EF, and Rijken DC (1997) On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 272:14477-14482.
30. Schroeder V, Chatterjee T, Mehta H, Windecker S, Pham T, Devantay N, Meier B, and Kohler HP (2002) Thrombin activatable fibrinolysis inhibitor (TAFI) levels in patients with coronary artery disease investigated by angiography. Thromb Haemost 88:1020-1025.
31. Schatteman KA, Goossens FJ, Scharpe SS, and Hendriks DF (1999) Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb Haemost 82:1718-1721.
32. Skidgel RA, Deddish PA, and Davis RM (1988) Isolation and characterization of a basic carboxypeptidase from human seminal plasma. Arch Biochem Biophys 267:660-667.
33. Speiser W, Anders E, Binder BR, and Muller-Berghaus G (1988) Clot lysis mediated by cultured human microvascular endothelial cells. Thromb Haemost 60:463-467.
34. Takahashi Y, Hosaka Y, Imada K, Adachi T, Niina H, Watanabe M, and Mochizuki H (1997) Human urinary soluble thrombomodulin (MR-33) improves disseminated intravascular coagulation without affecting bleeding time in rats: comparison with low molecular weight heparin. Thromb Haemost 77:789-795.
35. Tanaka T, Suda H, Naganawa H, Hamada M, Takeuchi T, Aoyagi T, and Umezawa H (1984) Production of (S)-alpha-benzylmalic acid, inhibitor of carboxypeptidase A by actinomycetes. J Antibiot (Tokyo) 37:682-684.
36. van Tilburg NH, Rosendaal FR, and Bertina RM (2000) Thrombin activatable fibrinolysis inhibitor and risk for deep vein thrombosis. Blood 95:2855-2859.
37. Vassiliou S, Mucha A, Cuniasse P, Georgiadis D, Lucet-Levannier K, Beau F, Kannan R, Murphy G, Knauper V, Rio MC, et al. (1999) Phosphinic pseudotripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J Med Chem 42:2610-2620.
38. Weitz JI, Leslie B, Hirsh J, and Klement P (1993) Alpha 2-antiplasmin supplementation inhibits tissue plasminogen activator-induced fibrinogenolysis and bleeding with little effect on thrombolysis. J Clin Investig 91:1343-1350.
39. Zorio E, Castello R, Falco C, Espana F, Osa A, Almenar L, Aznar J, and Estelles A (2003) Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system. Br J Haematol 122:958-965.